Adenovir Pharma AB

Adenovir Pharma AB, founded in 2008, is a biopharmaceutical company based in Helsingborg, Sweden, specializing in innovative treatments for infectious eye diseases. The company collaborates with P.U.L.S. AB, an incubator and financier for early-stage life science projects, and has received a $787.00K Venture Round investment from notable investors including Augmenta, Länsförsäkringar, PULS, and Sätila Holding on 15th June 2010. Adenovir Pharma leverages its location within Medicon Valley, Europe's leading biotechnology region, and its partnerships with the University of Lund's Department of Organic Chemistry and Umeå University's Department of Virology, as well as various external service providers, to advance its research and development initiatives. The company's focus on developing an antiviral medicinal product to treat and prevent epidemic keratoconjunctivitis (EKC) aligns with its commitment to providing new treatment options and business opportunities for the pharmaceutical industry through its unique patented technology and proprietary product concepts.